We are international
trials TEXT SIZE   

Pomalyst® is the newest oral immun­omodulatory drug (IMiD®). Approved by the FDA in 2013, Pomalyst is chemically related to thalidomide and lenalidomide, which was approved by the FDA in 2006, but Pomalyst has been enhanced to be more effective.

Pomalyst® (pomalidomide) capsules

02.25.13   Understanding Pomalyst®
(pomalidomide) capsules

The U.S. Food and Drug Administration (FDA) approved Pomalyst® (pomalidomide) on February 8, 2013, to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

The National Comprehensive Cancer Network (NCNN) has included pomalidomide plus dexamethasone as a salvage therapy option in patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. For steroid-intolerant individuals, the NCNN Multiple Myeloma Panel suggests considering pomalidomide monotherapy.

02.25.13   Pomalyst® (pomalidomide) capsules Tip Card

09.27.12   PEXIUS: Expanded access program for pomalidomide
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

12.01.09   Pomalidomide on clinicaltrials.gov
Like lenalidomide, pomalidomide is an immunomodulatory derivative (IMiD) of thalidomide. Approved by the FDA in 2013, alone and in combination with other drugs, it is showing clinical activity and is well-tolerated in patients who have relapsed after multiple prior therapies and are refractory to both lenalidomide and bortezomib.